Skip to main content
SpringerLink
Log in

Clindamycin hydrochloride and clindamycin phosphate: two drugs or one? A retrospective analysis of a spontaneous reporting system

  • Letter to the Editor
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Lammintausta K, Tokola R, Kalimo K (2002) Cutaneous adverse reactions to clindamycin: results of skin tests and oral exposure. Br J Dermatol 146:643–658. doi:10.1046/j.1365-2133.2002.04665.x

    Article  CAS  PubMed  Google Scholar 

  2. The DrugBank database. Available at: http://www.drugbank.ca/drugs/DB01190. Accessed 10 Aug 2016

  3. Stanković M, Savić V, Marinković V (2013) Determination of clindamycin phosphate in different vaginal gel formulations by reverse phase high performance liquid chromatography. Acta Facultatis Medicae Naissensis 30(2):63–71. doi:10.2478/v10283-012-0038-y

    Google Scholar 

  4. Lell B, Kremsner PG (2002) Clindamycin as an antimalarial drug: review of clinical trials. Antimicrob Agents Chemother 46(8):2315–2320. doi:10.1128/AAC.46.8.2315-2320.2002

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. American Society of Health-System Pharmacists (2012) Drug information 2012. Bethesda, MD, p 475

  6. Priscilla KS, Kenneth F (2005) The investigation of hematuria. Semin Nephrol 25(3):127–135. doi:10.1016/j.semnephrol.2005.01.002

    Article  Google Scholar 

  7. Li H, Deng J, Yue Z, Zhang Y, Sun H (2015) Detecting drug-herbal interaction using a spontaneous reporting system database: an example with benzylpenicillin and qingkailing injection. Eur J Clin Pharmacol 71(9):1139–1145. doi:10.1007/s00228-015-1898-8

    Article  CAS  PubMed  Google Scholar 

  8. Egberts AC, Meyboom RH, van Puijenbroek EP (2002) Use of measures of disproportionality in pharmacovigilance: three Dutch examples. Drug Saf 25:453–458. doi:10.2165/00002018-200225060-00010

    Article  PubMed  Google Scholar 

  9. Rothman KJ, Lanes S, Sacks ST (2004) The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf 13(8):519–523. doi:10.1002/pds.1001

    Article  PubMed  Google Scholar 

  10. Caster O, Norén GN, Madigan D, Bate A (2010) Large-scale regression-based pattern discovery: the example of screening the WHO global drug safety database. Stat Anal Data Min 3(4):197–208. doi:10.1002/sam.10078

    Google Scholar 

  11. Qian Y, Ye X, Du W, Ren J, Sun Y, Wang H, Luo B, Gao Q, Wu M, He J (2010) A computerized system for detecting signals due to drug-drug interactions in spontaneous reporting systems. Br J Clin Pharmacol 69(1):67–73. doi:10.1111/j.1365-2125.2009.03557.x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Hochberg AM, Pearson RK, O’Hara DJ, Reisinger SJ (2009) Drug-versus-drug adverse event rate comparisons: a pilot study based on data from the US FDA Adverse Event Reporting System. Drug Saf 32:137–146. doi:10.2165/00002018-200932020-00006

    Article  CAS  PubMed  Google Scholar 

  13. Lindquist M, Ståhl M, Bate A, Edwards IR, Meyboom RH (2000) A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database. Drug Saf 23:533–542. doi:10.2165/00002018-200023060-00004

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Huaihe Hospital of Henan University, Henan University, Kaifeng, 475004, Henan, People’s Republic of China

    Haona Li & Xuequn Ren

  2. Adverse Drug Reaction Monitoring Centre of Guangdong Province, Guangzhou, People’s Republic of China

    Jianxiong Deng & Yiexiang Zhang

  3. Chinese Pharmacopoeia Commission, Beijing, People’s Republic of China

    Zhihua Yue

  4. Tasly Research and Development Institute, Tasly Pharmaceutical Co., Ltd., Tianjin, People’s Republic of China

    He Sun

  5. School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, People’s Republic of China

    He Sun

Authors
  1. Haona Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jianxiong Deng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhihua Yue
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yiexiang Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. He Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xuequn Ren
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Haona Li or Xuequn Ren.

Ethics declarations

Conflict of interest

The authors have no conflicts of interest to declare.

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1

(DOCX 89 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, H., Deng, J., Yue, Z. et al. Clindamycin hydrochloride and clindamycin phosphate: two drugs or one? A retrospective analysis of a spontaneous reporting system. Eur J Clin Pharmacol 73, 251–253 (2017). https://doi.org/10.1007/s00228-016-2161-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-016-2161-7

Keywords

Search

Navigation